Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer.
Slightly overvalued with limited growth.
Share Price & News
How has Agenus's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AJ81's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: AJ81 underperformed the German Biotechs industry which returned -5.1% over the past year.
Return vs Market: AJ81 matched the German Market which returned -17.7% over the past year.
Price Volatility Vs. Market
How volatile is Agenus's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Agenus undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AJ81 (€2.15) is trading below our estimate of fair value (€6.44)
Significantly Below Fair Value: AJ81 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AJ81 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: AJ81 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AJ81's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AJ81 has negative assets, so we can't compare its PB Ratio to the DE Biotechs industry average.
How is Agenus forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AJ81 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AJ81 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AJ81 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AJ81's revenue (25.7% per year) is forecast to grow faster than the German market (4.1% per year).
High Growth Revenue: AJ81's revenue (25.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AJ81's Return on Equity is forecast to be high in 3 years time
How has Agenus performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AJ81 is currently unprofitable.
Growing Profit Margin: AJ81 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AJ81 is unprofitable, and losses have increased over the past 5 years at a rate of -10.9% per year.
Accelerating Growth: Unable to compare AJ81's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AJ81 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).
Return on Equity
High ROE: AJ81's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Agenus's financial position?
Financial Position Analysis
Short Term Liabilities: AJ81 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: AJ81 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: AJ81 has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: AJ81's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Inventory Level: AJ81 has a high level of physical assets or inventory.
Debt Coverage by Assets: AJ81 has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AJ81 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AJ81 has less than a year of cash runway if free cash flow continues to reduce at historical rates of -11.7% each year
What is Agenus's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AJ81's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate AJ81's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AJ81's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AJ81's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AJ81's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Garo Armen (66yo)
Dr. Garo H. Armen, Ph.D., founded Agenus Inc. in 1994 and has been its Chief Executive Officer since 1994. Dr. Armen serves as an Executive Chairman of Agenus Inc. He has been an Executive Director of Agen ...
CEO Compensation Analysis
Compensation vs Market: Garo's total compensation ($USD2.57M) is above average for companies of similar size in the German market ($USD1.03M).
Compensation vs Earnings: Garo's compensation has been consistent with company performance over the past year.
|President & COO||0.17yr||US$986.47k||0.022% $76.0k|
|VP of Finance||0.58yr||US$497.48k||no data|
|VP of Investor Relations & Communications||no data||no data||no data|
|VP, General Counsel & Secretary||1.67yrs||no data||0.0080% $27.5k|
|Chief Commercial Officer & Head of HR||2.67yrs||US$461.73k||no data|
|Head of Translational Medicine & Bioinformatics||2.17yrs||no data||no data|
|Global Head of Clinical Operations||1yr||no data||no data|
|VP & Head of Commercial||0.67yr||no data||no data|
|Vice President of Cellular Immunology||no data||no data||no data|
Experienced Management: AJ81's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
|Independent Director||3.83yrs||US$195.08k||0.038% $131.8k|
|Independent Director||17yrs||US$113.70k||no data|
|Lead Director||11.17yrs||US$218.70k||0.021% $71.5k|
|Independent Director||13yrs||US$257.58k||0.026% $90.5k|
Experienced Board: AJ81's board of directors are seasoned and experienced ( 11.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21.9%.
Agenus Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Agenus Inc.
- Ticker: AJ81
- Exchange: DB
- Founded: 1994
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$379.736m
- Listing Market Cap: US$344.193m
- Shares outstanding: 161.59m
- Website: https://agenusbio.com
Number of Employees
- Agenus Inc.
- 3 Forbes Road
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AGEN||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Feb 2000|
|AJ81||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Feb 2000|
|AJ81||BRSE (Berne Stock Exchange)||Yes||Common Stock||CH||CHF||Feb 2000|
Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neoantigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neoepitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/30 20:47|
|End of Day Share Price||2020/03/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.